Edgar Filing: JORDAN WADIH - Form 4

Form 4	H									
June 22, 2018										
FORM 4	UNITED	статес	SECU	DITIES				NT.	PPROVAL	
Washington, D.C. 20549								Number:	3235-0287 January 31,	
Check this box if no longer		STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF								
subject to Section 16. Form 4 or			burden hou response	irs per						
Form 5 obligations may continue. See Instruction 1(b). Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940										
(Print or Type Respo	nses)									
1. Name and Address of Reporting Person <u>*</u> JORDAN WADIH			2. Issuer Name and Ticker or Trading Symbol AGENUS INC [AGEN]			5. Relationship of Reporting Person(s) to Issuer				
(Last)	(First) (Middle) 3. Date of Earliest Transaction					(Ch	eck all applicable	k all applicable)		
ANTIGENICS INC., 149 FIFTH AVE., SUITE 500			(Month/Day/Year) 06/20/2018			XDirector10% Owner Officer (give titleOther (specify below)below)				
	(Street) 4. If Amendment, Date Original Filed(Month/Day/Year)			1	 6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person Form filed by More than One Reporting 					
NEW YORK, N	Y 10010						Person	More than One Ro	eporung	
(City)	(State)	(Zip)	Tab	le I - Non-	Derivative	Securities A	Acquired, Disposed	of, or Beneficia	lly Owned	
1.Title of Security (Instr. 3)2. Transaction Date (Month/Day/Year)2A. Deem Execution any (Month/D		Date, if TransactionA Code D		4. Securit onAcquired Disposed (Instr. 3, 4	(A) or of (D)	5. Amount of Securities Beneficially Owned Following Reported	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)		
				Code V	Amount	or (D) Price	Transaction(s) (Instr. 3 and 4)			
Reminder: Report or	n a separate line	for each cla	ass of sec	urities bene	ficially ow	ned directly	or indirectly.			
					inforn requir	nation cont red to resp iys a curre	spond to the colle tained in this forn ond unless the fo ntly valid OMB co	n are not rm	SEC 1474 (9-02)	

 Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
 (e.g., puts, calls, warrants, options, convertible securities)

1. Title of	2.	3. Transaction Date	3A. Deemed	4.	5. Number of	6. Date Exercisable and	7. Title and Amount
Derivative	Conversion	(Month/Day/Year)	Execution Date, if	Transacti	orDerivative	Expiration Date	Underlying Securities
Security	or Exercise		any	Code	Securities	(Month/Day/Year)	(Instr. 3 and 4)

Edgar Filing: JORDAN WADIH - Form 4

(Instr. 3)	Price of Derivative Security	ivative		(Instr. 8)	Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)					
				Code V	(A) ((D)	Date Exercisable	Expiration Date	Title	Amour or Numbe of Shar
Common Stock	\$ 5.65	06/20/2018		А	37,500		03/02/2019(1)	03/02/2028	Common Stock	37,50

Reporting Owners

Reporting Owner Name / Address	Relationships					
	Director	10% Owner	Officer	Other		
JORDAN WADIH ANTIGENICS INC. 149 FIFTH AVE., SUITE 500 NEW YORK, NY 10010	Х					
Signatures						
Christine M. Klaskin, by Power Attorney	of	06/	22/2018			

**Signature of Reporting Person

Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Option was granted on March 2, 2018 subject to shareholder approval, which was obtained at the Company's annual shareholder meeting
 (1) on June 20, 2018. Option awarded in accordance with the Agenus Inc. Amended and Restated 2009 Equity Incentive Plan, vesting on March 2, 2019.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.